GPA33抗体

+ +

•  

   

     Gel: 15%SDS-PAGE, Lysate: 40 μg, Lane 1-3: 293T cells, human colon cancer tissue, 231 cells, Primary antibody: P07322(GPA33 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07322(GPA33 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07322(GPA33 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The GPA33 (Glycoprotein A33) antibody targets a cell surface antigen belonging to the immunoglobulin superfamily, initially identified for its selective expression in gastrointestinal epithelial cells and over 95% of colorectal carcinomas. Discovered in the 1990s, GPA33 is a transmembrane glycoprotein with two extracellular immunoglobulin-like domains (IgV and IgC2) and a glycosylphosphatidylinositol (GPI) anchor. Its restricted expression in normal tissues—primarily the intestines—and high prevalence in tumors make it a promising target for antibody-based cancer therapies.

Research highlights GPA33's role in cell-cell adhesion and signaling, though its exact biological function remains unclear. Preclinical studies demonstrated that monoclonal antibodies against GPA33. such as murine A33. exhibit potent antitumor activity via mechanisms like antibody-dependent cellular cytotoxicity (ADCC) or as carriers for radioisotopes or drug conjugates. Clinical trials explored chimeric or humanized A33 antibodies for colorectal cancer, though efficacy was limited by tumor heterogeneity and immune evasion.

Recent interest focuses on combining GPA33-targeting antibodies with immune checkpoint inhibitors or engineered T-cell therapies to enhance specificity and reduce off-target effects. Its tumor-selective profile continues to drive investigations into diagnostic imaging, targeted drug delivery, and immunotherapy strategies for gastrointestinal malignancies.